Congress Just Introduced a Bill to Shut Down Compounded Peptides

Is it true that buying peptides may be shut down by the government? The short answer is, well, the short answer is, the short answer is it depends on what you're buying and where you're getting it from.

But there's a lot more to this than the headlines are giving you, because the headlines are covering a bill and the bill is really the last step in a four year fight that started with a supply problem and ended with a market being closed.

You see, within the last few days, there was a bill pushed through Congress looking to amend the Federal Food, Drug and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities.

So basically what Congress is looking to do in the name of keeping you safe is limiting your ability to access affordable peptides and GLP medications.

In this video, I'm going to explain exactly what this bill is intended to do and how it's going to affect you. Because if you don't understand what happened over the last few, because if you don't understand what happened over the last few years, none of this is going to make any sense to you.

Start with how the legal structure actually works, because that's the piece most people are missing. Under federal law there are two kinds of pharmacies that make drugs outside of a manufacturer's factory, and they're named after the sections of the law that created them. A 503A pharmacy compounds for individual patients with individual prescriptions, and a 503B outsourcing facility compounds in larger batches for clinics and hospitals without a patient name attached to each vial. Both of them are allowed to exist because doctors sometimes need a version of a drug that the manufacturer doesn't sell, a different concentration, a preservative free version, a liquid for someone who can't swallow a pill.

But the deal has always had a hard boundary on it, which is that a compounding pharmacy cannot make something that is essentially a copy of an FDA approved commercial drug, and if the manufacturer makes it, you're expected to buy it from the manufacturer, since that single restriction is really what the whole fight comes down to. If the manufacturer makes it, you buy it from the manufacturer.

Back in 2022, Terzepotide and Semiglutide were placed on the FDA drug shortage list. These are the active ingredients in Mounjaro, Zepbound, Ozempic and Wegovy, and Eli Lilly and Novo Nordisk simply could not produce enough of them to meet what the market wanted.

The shortage list is the one legal door in that wall. When a drug is on it, the essentially a copy restriction gets lifted, because the reasoning is that a patient who can't get the real drug is worse off than a patient who gets a compounded version of it.

Compound pharmacies were allowed to produce off-label versions of these drugs during the shortage, and this created a surge of very affordable options.

Terzepotide through a compounding pharmacy costs somewhere between $200 and $400 per month, while the brand name version costs over $1,000. So you can imagine what that did to Eli Lilly's profit margins, and more importantly, you can imagine what it did to their pricing power long term, because once a few million people have anchored on $300 a month, going back to $1,000 is a much harder sell.

The timeline clicks into place once you notice who actually controls the shortage list, because it isn't patients and it isn't pharmacies. It's controlled by what the manufacturer tells the FDA about its own production capacity, which means the company that loses money from compounding also holds the switch that turns compounding off.

Eli Lilly saw the writing on the wall, and since 2020 they've invested over $18 billion into manufacturing capacity spread across facilities in the U.S. and in Europe.

And in just May of 2024 alone, they announced a $5.3 billion expansion at their Indiana facility, bringing total investment in that site to $9 billion.

Then in October 2024, they told the FDA they could now meet demand, and the FDA declared the terzepotide shortage resolved.

But people across the country were still having trouble getting these drugs. Prescriptions for type 2 diabetes were going unfilled, pharmacies were still back ordered, and the shortage was over on paper because the manufacturer said it was over, which is a different thing from being over at the counter where a patient is standing.

Well, a week after the FDA declared that shortage resolved, the Outsourcing Facilities Association sued the FDA. They called the decision reckless and arbitrary, and they argued the agency had taken the manufacturer's word over the lived experience of the people trying to fill scripts.

The FDA paused, reassessed, and then in December of 2024, they confirmed their original call, and the shortage stayed resolved on their books.

Eli Lilly filed to join the FDA as a defendant in that lawsuit. Think about that arrangement for a second, because the company whose sales data closed the shortage was now in court on the same side as the regulator, defending the decision that its own data produced.

Compounding pharmacies started receiving cease and desist letters, which is what you've been hearing about on social media all year, and one by one they lost the ability to keep producing terzepotide.

Then in February 2025, semaglutide was also removed from the shortage list, following almost the identical pattern and landing on almost the identical result.

On December 9th, 2025, a new bill was introduced in Congress. It's called the Safe Drugs Act of 2025.

The first thing it does is write the essentially a copy definition directly into statute, so any compounded drug with the same active ingredient as an FDA approved medicine is a copy, full stop. Adding vitamin B12 or adjusting the dose no longer counts as a workaround.

That single line closes the door that most of the industry had been standing in. When the cease and desist letters went out, a lot of pharmacies pivoted to semaglutide plus B12, or to a 2.7mg dose that didn't match any commercial strength, and the argument was that a different formulation isn't a copy. This bill says the active ingredient is what matters and the additives don't buy you anything.

Second, the bill puts a hard ceiling on how much a pharmacy can produce. Compounding pharmacies are now limited to 20 copies per month, which kills mass production, because a telehealth operation serving thousands of patients cannot survive on twenty units.

If a pharmacy ships more than 20 out of state prescriptions, they have to report that activity to the FDA. And fourth, it requires pre-production inspections, so large scale operations need to be inspected before they start and re-inspected every two years.

That last one sounds like a formality and it isn't. Inspection scheduling is a resource question at the agency level, and a facility waiting on an inspection date is a facility that isn't producing, which means the timeline itself becomes the limit regardless of whether anyone is ever denied.

So what does all this mean in plain language? Well, this bill codifies into law what Eli Lilly and Novo Nordisk have been fighting for in courts, and that distinction matters because court rulings can be appealed and shortage designations can come back, while a statute just sits there, fixed, immune to that kind of reversal.

This bill is supported by the American Diabetes Association, the Obesity Action Coalition, and the Partnership for Safe Medicines. Sounds pretty legit, right? Well, all these organizations also receive pharmaceutical industry funding from companies like Eli Lilly and Novo Nordisk.

And the language in the bill about weakening incentives to develop new treatments is pharma speak for protecting profit margins, since the concern on the page has very little to do with your health and everything to do with locking the market down.

Now for the question everybody actually has, which is what happens to research grade peptides.

This bill specifically targets 503A and 503B compounding pharmacies. Research chemical suppliers operate under a different legal framework entirely, so on paper the bill does not touch them.

But the pressure on that side of the market is already happening through a separate channel. The FDA has already been sending warning letters to research peptide suppliers throughout 2024 and 2025, and companies selling retatrutide, semaglutide, terzepatide and cagrilintide have been the ones getting targeted.

The women's group is where this gets worked through with the coaches, and it is free, so if you want the rest of it and somewhere to ask, it is here: https://www.skool.com/powerhouse-fitness-for-women/about